Yutong Zou
Zhuhai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Observational study of nailfold capillaroscopy features in hypertension, diabetes Mellitus, stroke, and chronic kidney disease: Associations and potential for early detection in cardiovascular and metabolic disorders.
Journal: Clinical hemorheology and microcirculation
Published: April 20, 2026
LIPA-driven reprogramming of tumor-associated macrophages shapes an immunosuppressive microenvironment in osteosarcoma.
Journal: International immunopharmacology
Published: November 11, 2025
Tumor Extracellular Vesicles lncOSLMT Drives Lung Inflammatory Premetastatic Niche Formation in Osteosarcoma via m6A-Dependent hnRNPA2B1/COX-2 Axis.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: October 02, 2025
Multiomics integration analysis identifies tumor cell-derived MIF as a therapeutic target and potentiates anti-PD-1 therapy in osteosarcoma.
Journal: Journal for immunotherapy of cancer
Published: July 19, 2025
Single-cell profiling of SLC family transporters: uncovering the role of SLC7A1 in osteosarcoma.
Journal: Journal of translational medicine
Published: October 22, 2024
PABPN1-C5 axis promotes hepatocellular carcinoma progression via NF-κB activation.
Journal: Oncogene
Published: September 12, 2024
A diagnostic signature developed based on the necroptosis-related genes and its association with immune infiltration in osteosarcoma.
Journal: Heliyon
Published: May 27, 2024
PAPOLA-mediated hyperactive polyadenylation promotes leukemogenesis and leukemia stem cell self-renewal through metabolic reprogramming.
Journal: Nature cancer
Published: January 23, 2024
Ceramide metabolism-related prognostic signature and immunosuppressive function of ST3GAL1 in osteosarcoma.
Journal: Translational oncology
Published: September 30, 2023
Construction of an ER stress-related prognostic signature for predicting prognosis and screening the effective anti-tumor drug in osteosarcoma.
Journal: Journal of translational medicine
Published: August 22, 2023
Targeting NAT10 inhibits osteosarcoma progression via ATF4/ASNS-mediated asparagine biosynthesis.
Journal: Cell reports. Medicine
Published: August 08, 2023
Last Updated: 09/26/2026